nach oben

Erschienen in:

19.08.2020

An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score

verfasst von: Welmoed K. van Deen, Alexandra Obremskey, Graham Moore, M. Elske van den Akker-van Marle, Jason N. Doctor, Caroline Hwang

Erschienen in: Quality of Life Research | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Inflammatory bowel disease (IBD) patients experience diverse symptoms and the impact of these different symptoms varies substantially. Current disease activity measures do not account for the relative importance of the different symptoms and severity levels. In this study, we aimed to quantify the relative importance of different symptoms for IBD patients and to develop a patient preference-weighted symptom (PWS) score to assess symptom burden in IBD.

Methods

We performed a choice-based conjoint analysis (CBCA) survey with 129 IBD patients to estimate the relative importance of four common IBD symptoms: stool frequency, abdominal pain, blood in stools, and urgency. We then developed the PWS score using the preferences obtained from the CBCA, which we validated against existing measures.

Results

CBCA revealed that urgency was the most important symptom to patients, followed by abdominal pain and blood in stools. Urgency associated with incontinence received particularly high scores and was perceived to be more than 3 times as important as urgency without incontinence. Our results confirmed that different symptoms are not equally bothersome, and we showed that the relation between symptom-level and importance is not linear. The PWS score, which we developed using these estimates was highly correlated with existing disease activity measures.

Conclusions

We quantified the relative importance of four common IBD symptoms and developed the PWS score for IBD, which takes the relative importance of different symptoms and symptom-levels into account. The PWS score can be used to obtain a patient-centered assessment of symptom burden.

Nur mit Berechtigung zugänglich

Farrell, D., McCarthy, G., & Savage, E. (2016). Self-reported Symptom Burden in Individuals with Inflammatory Bowel Disease. Journal of Crohns Colitis, 10(3), 315–322. https://doi.org/10.1093/ecco-jcc/jjv218.CrossRef

Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F., Jr. (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 70(3), 439–444.CrossRef

Harvey, R., & Bradshaw, J. (1980). A simple index of Crohn's-disease activity. The Lancet, 315(8167), 514.CrossRef

Lewis, J. D., Chuai, S., Nessel, L., Lichtenstein, G. R., Aberra, F. N., & Ellenberg, J. H. (2008). Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflammatory Bowel Diseases, 14(12), 1660–1666. https://doi.org/10.1002/ibd.20520.CrossRefPubMedPubMedCentral

Walmsley, R. S., Ayres, R. C., Pounder, R. E., & Allan, R. N. (1998). A simple clinical colitis activity index. Gut, 43(1), 29–32.CrossRef

Falvey, J. D., Hoskin, T., Meijer, B., Ashcroft, A., Walmsley, R., Day, A. S., et al. (2015). Disease activity assessment in IBD: Clinical indices and biomarkers fail to predict endoscopic remission. Inflammatory Bowel Diseases, 21(4), 824–831. https://doi.org/10.1097/MIB.0000000000000341.CrossRefPubMed

Khanna, R., Zou, G., D'Haens, G., Feagan, B. G., Sandborn, W. J., Vandervoort, M. K., et al. (2015). A retrospective analysis: The development of patient reported outcome measures for the assessment of Crohn's disease activity. Alimentary Pharmacology & Therapeutics, 41(1), 77–86. https://doi.org/10.1111/apt.13001.CrossRef

Jairath, V., Khanna, R., Zou, G. Y., Stitt, L., Mosli, M., Vandervoort, M. K., et al. (2015). Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Alimentary Pharmacology & Therapeutics, 42(10), 1200–1210. https://doi.org/10.1111/apt.13408.CrossRef

Spiegel, B. M., Hays, R. D., Bolus, R., Melmed, G. Y., Chang, L., Whitman, C., et al. (2014). Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. American Journal of Gastroenterology, 109(11), 1804–1814. https://doi.org/10.1038/ajg.2014.237.CrossRefPubMed

10.

Kochar, B., Martin, C. F., Kappelman, M. D., Spiegel, B. M., Chen, W., Sandler, R. S., et al. (2018). Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) symptom scales in subjects with inflammatory Bowel diseases. American Journal of Gastroenterology, 113(1), 72–79. https://doi.org/10.1038/ajg.2017.240.CrossRefPubMed

11.

Craig, B. M., Reeve, B. B., Brown, P. M., Cella, D., Hays, R. D., Lipscomb, J., et al. (2014). US valuation of health outcomes measured using the PROMIS-29. Value Health, 17(8), 846–853. https://doi.org/10.1016/j.jval.2014.09.005.CrossRefPubMedPubMedCentral

12.

Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22. https://doi.org/10.1002/hec.3564.CrossRefPubMed

13.

Mohamed, A. F., Hauber, A. B., Johnson, F. R., & Coon, C. D. (2010). Patient preferences and linear scoring rules for patient-reported outcomes. The Patient: Patient-Centered Outcomes Research, 3(4), 217–227.CrossRef

14.

Alrubaiy, L., Rikaby, I., Sageer, M., Hutchings, H. A., & Williams, J. G. (2015). Systematic review of the clinical disease severity indices for inflammatory bowel disease. Inflammatory Bowel Diseases, 21(10), 2460–2466. https://doi.org/10.1097/MIB.0000000000000438.CrossRefPubMed

15.

Bridges, J. F., Hauber, A. B., Marshall, D., Lloyd, A., Prosser, L. A., Regier, D. A., et al. (2011). Conjoint analysis applications in health—A checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health, 14(4), 403–413. https://doi.org/10.1016/j.jval.2010.11.013.CrossRefPubMed

16.

Ryan, M., & Farrar, S. (2000). Using conjoint analysis to elicit preferences for health care. BMJ, 320(7248), 1530–1533.CrossRef

17.

Walsh, A. J., Bryant, R. V., & Travis, S. P. (2016). Current best practice for disease activity assessment in IBD. Nature Reviews Gastroenterology & Hepatology, 13(10), 567.CrossRef

18.

The CBC System for Choice-Based Conjoint Analysis. Version 9 (2017). Sawtooth Software Technical Paper Series.

19.

Sawtooth Software, CBC/HB v5, Software for Hierarchical Bayes Estimation for CBC Data. Manual. Retrieved July 23, 2020, from https://www.sawtoothsoftware.com/download/techpap/CBCHB_Manual.pdf.

20.

Hauber, A. B., Gonzalez, J. M., Groothuis-Oudshoorn, C. G., Prior, T., Marshall, D. A., Cunningham, C., et al. (2016). Statistical methods for the analysis of discrete choice experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health, 19(4), 300–315. https://doi.org/10.1016/j.jval.2016.04.004.CrossRefPubMed

21.

Orme, B., & Johnson, R. (2014). Including holdout choice tasks in conjoint studies. Sawtooth Software, Inc. Retrieved July 23, 2020. from https://www.sawtoothsoftware.com/support/technical-papers/general-conjoint-analysis/including-holdout-choice-tasks-in-conjoint-studies-2014.

22.

Chrzan, K., Zepp, J., & White, J. (2010). The success of choice-based conjoint designs among respondents making lexicographic choices. In 2010 Sawtooth Software Conference Proceedings (pp. 19–35). Newport Beach, CA.

23.

Lancsar, E., & Louviere, J. (2006). Deleting ‘irrational’responses from discrete choice experiments: A case of investigating or imposing preferences? Health Economics, 15(8), 797–811.CrossRef

24.

Hess, S., Rose, J. M., & Polak, J. (2010). Non-trading, lexicographic and inconsistent behaviour in stated choice data. Transportation Research Part D: Transport and Environment, 15(7), 405–417.CrossRef

25.

Evertsz, F. B., Hoeks, C. C., Nieuwkerk, P. T., Stokkers, P. C., Ponsioen, C. Y., Bockting, C. L., et al. (2013). Development of the patient harvey bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn's disease activity. Journal of Clinical Gastroenterology, 47(10), 850–856. https://doi.org/10.1097/MCG.0b013e31828b2196.CrossRef

26.

Orme, B. (2010). Getting started with conjoint analysis: Strategies for product design and pricing research (2nd ed.). Madison, WS: Research Publishers LLC.

27.

Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care, 42(9), 851–859.CrossRef

28.

Bossuyt, P., & Vermeire, S. (2016). Treat to target in inflammatory bowel disease. Current Treatment Options in Gastroenterology, 14(1), 61–72.CrossRef

29.

Colombel, J.-F., Panaccione, R., Bossuyt, P., Lukas, M., Baert, F., Vaňásek, T., et al. (2017). Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet, 390(10114), 2779–2789.CrossRef

30.

Mueller, S., Lockshin, L., & Louviere, J. J. (2010). What you see may not be what you get: Asking consumers what matters may not reflect what they choose. Marketing Letters, 21(4), 335–350.CrossRef

Titel: An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score
verfasst von: Welmoed K. van Deen
Alexandra Obremskey
Graham Moore
M. Elske van den Akker-van Marle
Jason N. Doctor
Caroline Hwang
Publikationsdatum: 19.08.2020
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 12/2020
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02606-2

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial

Reliability, construct validity, and measurement invariance of the PROMIS Physical Function 8b—Adult Short Form v2.0

Relationship between family functioning and health-related quality of life among methadone maintenance patients: a Bayesian approach

Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD)

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer